These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 12654251)

  • 41. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
    Pisabarro MT; Serrano L; Wilmanns M
    J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.
    Agafonov RV; Wilson C; Otten R; Buosi V; Kern D
    Nat Struct Mol Biol; 2014 Oct; 21(10):848-53. PubMed ID: 25218445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulation of Cbl phosphorylation by the Abl tyrosine kinase and the Nck SH2/SH3 adaptor.
    Miyoshi-Akiyama T; Aleman LM; Smith JM; Adler CE; Mayer BJ
    Oncogene; 2001 Jul; 20(30):4058-69. PubMed ID: 11494134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancement of ABL kinase catalytic efficiency by a direct binding regulator is independent of other regulatory mechanisms.
    Cao X; Tanis KQ; Koleske AJ; Colicelli J
    J Biol Chem; 2008 Nov; 283(46):31401-7. PubMed ID: 18796434
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
    Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM
    Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gleevec target Abl important for normal immune activation of T cells.
    Cancer Biol Ther; 2004 Aug; 3(8):704. PubMed ID: 15751157
    [No Abstract]   [Full Text] [Related]  

  • 47. Abl N-terminal cap stabilization of SH3 domain dynamics.
    Chen S; Dumitrescu TP; Smithgall TE; Engen JR
    Biochemistry; 2008 May; 47(21):5795-803. PubMed ID: 18452309
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
    Dietrich J; Hulme C; Hurley LH
    Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
    Roumiantsev S; Shah NP; Gorre ME; Nicoll J; Brasher BB; Sawyers CL; Van Etten RA
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10700-5. PubMed ID: 12149456
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Small molecule recognition of c-Src via the Imatinib-binding conformation.
    Dar AC; Lopez MS; Shokat KM
    Chem Biol; 2008 Oct; 15(10):1015-22. PubMed ID: 18940662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
    Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
    Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase.
    Dorey K; Engen JR; Kretzschmar J; Wilm M; Neubauer G; Schindler T; Superti-Furga G
    Oncogene; 2001 Dec; 20(56):8075-84. PubMed ID: 11781820
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
    Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
    J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer: Escape from inhibition.
    Courtneidge SA
    Nature; 2003 Apr; 422(6934):827-8. PubMed ID: 12712187
    [No Abstract]   [Full Text] [Related]  

  • 55. Activity of FB2, a novel dual Abl/Src tyrosine kinase inhibitor, against imatinib-resistant chronic myeloid leukemia in vivo and in vitro.
    Liu H; Li H; Feng Z; Tai J; Meng Y; Wang H; Xin H; Zhang S; Zuo M; Zhang Y; Chen X
    Leuk Lymphoma; 2009 Mar; 50(3):437-46. PubMed ID: 19347730
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
    Liang X; Hajivandi M; Veach D; Wisniewski D; Clarkson B; Resh MD; Pope RM
    Proteomics; 2006 Aug; 6(16):4554-64. PubMed ID: 16858728
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Sattler M; Scheijen B; Weisberg E; Griffin JD
    Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mitotic phosphorylation rescues Abl from F-actin-mediated inhibition.
    Woodring PJ; Hunter T; Wang JY
    J Biol Chem; 2005 Mar; 280(11):10318-25. PubMed ID: 15632178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer research. Why some leukemia cells resist STI-571.
    Marx J
    Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
    [No Abstract]   [Full Text] [Related]  

  • 60. Insight into the allosteric inhibition of Abl kinase.
    Fallacara AL; Tintori C; Radi M; Schenone S; Botta M
    J Chem Inf Model; 2014 May; 54(5):1325-38. PubMed ID: 24787133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.